Dr Rupam Tripura
Contact information
Research groups
Rupam Tripura
Clinical Researcher
Dr Rupam Tripura is a clinical researcher based at the Mahidol-Oxford Topical Medicine Research Unit (MORU) research stations in Cambodia. The main focus of his work has been to conduct clinical trials to understand the nature of drug-resistant falciparum malaria in western Cambodia and to develop treatment regimens, and strategies to combat the spread of resistance.
In 2008-2010, after the first reports of artemisinin resistant falciparum malaria, he was involved in a trial to look at the effect of high-dose or split-dose artesunate against artemisinin-resistant falciparum in western Cambodia. In 2011-13, he led the research team in Pailin, a site for the Tracking Resistance to Artemisinins Collaboration study (TRAC), an open-label, multicentre clinical trial conducted. In 2014-16, he was involved in the Triple Artemisinin Combination (TRAC 2) study in western Cambodia, which evaluated the efficacy, safety, and tolerability of combining three antimalarial treatments against standard artemisinin combination therapy (ACT). During 2013-14, He led a series of community based epidemiological studies to understand asymptomatic plasmodium infections and explore whether these are a barrier to malaria elimination. Therefore, during 2015-17, he jointly led the Cambodian sites for a multicentre clinical trial entitled Targeted Malaria Elimination (TME) which evaluated the effectiveness, safety and acceptability of three round of mass drug administration (MDA) with dihydroartemisinin-piperaquine in areas of multidrug resistant falciparum malaria. Currently, he is conducting in a clinical trial in Northern and Western part of Cambodia which evaluates artemether-lumefantrine with or without amodiaquine. The aim is to develop a treatment regimen against multi-drug resistant falciparum malaria.
Key publications
-
The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial
von Seidlein L. et al, (2019), PLOS Medicine, 16, e1002745 - e1002745
-
A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages
Tripura R. et al, (2018), Clinical Infectious Diseases, 67, 817 - 826
-
Submicroscopic Plasmodium prevalence in relation to malaria incidence in 20 villages in western Cambodia
Tripura R. et al, (2017), Malaria Journal, 16
-
Persistent Plasmodium falciparum and Plasmodium vivax infections in a western Cambodian population: implications for prevention, treatment and elimination strategies
Tripura R. et al, (2016), Malaria Journal, 15
-
Effect of High-Dose or Split-Dose Artesunate on Parasite Clearance in Artemisinin-Resistant Falciparum Malaria
Das D. et al, (2013), Clinical Infectious Diseases, 56, e48 - e58
Recent publications
-
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study
Imwong M. et al, (2020), The Lancet Infectious Diseases, 20, 1470 - 1480
-
Tools to accelerate falciparum malaria elimination in Cambodia: a meeting report
Lek D. et al, (2020), Malaria Journal, 19
-
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
van der Pluijm RW. et al, (2020), The Lancet, 395, 1345 - 1360
-
Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials
Phommasone K. et al, (2020), PLOS ONE, 15, e0228190 - e0228190
-
Forest work and its implications for malaria elimination: a qualitative study
Sanann N. et al, (2019), Malaria Journal, 18